Travere Therapeutics (TVTX) Cash from Financing Activities (2013 - 2026)

Travere Therapeutics has reported Cash from Financing Activities for 14 years, with the latest figure at $4.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 13.07% year-over-year to $4.2 million; the trailing twelve-month figure through Mar 2026 stood at -$33.0 million (down 122.96% YoY), and the FY2025 full-year result was -$33.5 million, down 124.0% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $4.2 million, down from $26.7 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $217.0 million in Q1 2023, with the low at -$65.3 million in Q3 2025.
• Historically, Cash from Financing Activities has averaged $26.4 million across 5 years, with a median of $1.5 million in 2025.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities jumped 112092.74% — and 2025, when it slumped 142141.3%.
• Travere Therapeutics' Cash from Financing Activities stood at $1.2 million in 2022, then slumped by 89.26% to $124000.0 in 2023, then jumped by 112092.74% to $139.1 million in 2024, then sank by 80.82% to $26.7 million in 2025, then plunged by 84.24% to $4.2 million in 2026.
• The last three Cash from Financing Activities figures came in at $4.2 million (Q1 2026), $26.7 million (Q4 2025), and -$65.3 million (Q3 2025), per Business Quant data.